Igenica focuses on the discovery and development of antibodies and antibody-drug conjugates (ADCs) to treat cancer. The company describes itself as the only biotherapeutic firm that fully powers the ADC development spectrum from patient-based target and functional antibody discovery to generation and manufacturing of homogeneous ADCs. Its integrated discovery engine has produced a pipeline of site-specific ADC candidates and functional antibodies. Management said the newly raised capital will be used to advance IGN523 through early clinical trials assessing safety and clinical activity in acute myelogenous leukemia. Proceeds will also support continued discovery and development of new therapeutics based on its ADC platform to expand the pipeline and increase strategic flexibility. Igenica is backed by a group of life-science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. Igenica is a Burlingame, CA-based biopharmaceutical company developing antibody-based cancer medicines. Its core programs focus on a monoclonal antibody pipeline aimed at a broad range of oncology drug targets. The company has integrated technology platforms including sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Led by Executive Chairman David Goeddel, Ph.D., Igenica plans to advance its pipeline toward clinical trials. Financially, the company recently completed a $33M Series C financing to support those development efforts. Igenica is a Burlingame, CA-based biopharmaceutical company developing antibody-based cancer medicines. The company leverages two proprietary technology platforms: sTAg, designed to discover and prioritize novel tumor antigens, and iTAb, a functional in vivo antibody screening approach. Igenica completed a $24M Series B financing to support its programs. The financing is intended to expand and accelerate the company’s drug discovery and development efforts. No operating metrics or past funding rounds were disclosed in the article.

Total raised

$71M

Funding rounds

3

Latest round

Series C

Latest activity

Jan 2014